Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients
Immunotherapy has been a new standard for recurrent/metastatic head and neck cancers (R/M HNC). One of the prominent characteristics of cancer immunotherapy is the induction of immune memory followed by endure...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Gaili Chen, Qiuji Wu, Huangang Jiang, Zheng Li, Xinying Hua, Xiaoyan Hu, Haijun Yu, Conghua Xie and Yahua Zhong Tags: Letter to the Editor Source Type: research
More News: Cancer | Cancer & Oncology | COVID-19 | Head and Neck Cancer | Hematology | Immunotherapy | Pandemics